The Sugar Beat

• 'Poised on a Paradigm Shift': The REWIND and DECLARE Trials   Drs Harpreet Bajaj and Akshay Jain, coauthors of the Sugar Beat column, come together to discuss the results and clinical implications of the REWIND and DECLARE trials.
  Medscape Diabetes & Endocrinology, June 14, 2019
  4
• CREDENCE Takes SGLT2 Inhibitors 'to the Next Level' What are the clinical implications of the CREDENCE trial? Dr Harpreet Bajaj shares his perspective on this landmark study.
  Medscape Diabetes & Endocrinology, April 25, 2019
  7
• Fielding the Dangers of Fasting and Feasting With Diabetes Are you prepared to safely guide your Muslim patients with diabetes through Ramadan, their holy month of fasting? Here's what you need to know.
  Medscape Diabetes & Endocrinology, April 18, 2019
  31
• Diabetes 360: A Plan to Quell the 'Tsunami' of Diabetes Diabetes Canada's 360? framework can revolutionize diabetes prevention policies across the globe, says Harpreet Bajaj.
  Medscape Diabetes & Endocrinology, March 25, 2019
• Generic DPP-4 Inhibitors Would Be a 'Shot in the Arm' Dr Akshay Jain discusses the potential implications of a generic DPP-4 inhibitor for the management of type 2 diabetes that may soon enter the US market.
  Medscape Diabetes & Endocrinology, February 08, 2019
  8
• The Artificial Pancreas Has Arrived in Canada: What to Expect Dr Harpreet Bajaj discusses the first artificial pancreas that has been approved for use in Canada--what to expect, anticipated challenges, and learnings from experiences in the United States.
  Medscape Diabetes & Endocrinology, January 02, 2019
  1
• Surviving the Holidays With Diabetes Celebrating the holidays doesn't have to be a choice between losing glycemic control or missing out on the fun. Dr Akshay Jain provides some tips to help guide discussions on safe holiday eating.
  Medscape Diabetes & Endocrinology, November 14, 2018
• Dispelling the Myths About Obesity Is obesity a choice? Are people just lazy or suffering from 'food addiction'? Dr Akshay Jain responds to the results of a recent Medscape poll and says it's time to dispel the myths about obesity.
  Medscape Diabetes & Endocrinology, September 21, 2018
  316
• SGLT2 Inhibitors: Unreal Primary Prevention? These diabetes drugs offer cardiovascular benefits, but only in diabetes patients who already have CV disease, the author argues.
  Medscape Diabetes & Endocrinology, May 15, 2018
  12
• Alcohol Advice Demands Full Disclosure First What do you tell patients who ask about 'safe' alcohol intake--or who inquire about your own drinking habits?
  Medscape Diabetes & Endocrinology, February 15, 2018
  32
• CANVAS: Straight Talk Needed on Amputation Risk Can a meta-analysis of two different studies or data from observational studies overcome the clinical concern about the clear-cut amputation risk with canagliflozin seen in the CANVAS trial?
  Medscape Diabetes & Endocrinology, October 16, 2017
  6